Home > Newsletters > FDAnews Drug Daily Bulletin > High Court Could Review Preemption as Mutual Pharma Petitions
FDAnews Drug Daily Bulletin
Aug. 17, 2012 | Vol. 9 No. 162
High Court Could Review Preemption as Mutual Pharma Petitions
Generic preemption issues may again wind up before the Supreme Court as generic maker Mutual Pharmaceutical is calling on it to reverse an appeals court decision that upheld a $21 million jury award to a patient injured by Mutual’s sulindac. Mutual argues the First Circuit Court of Appeals ignored Supreme Court precedent and the decisions laid down by all of its sister courts.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.